Amgen, Inc. (NASDAQ:AMGN)

research

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

The short interest data are out for the February 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Since the beginning of the year, there has been a flood of biotech initial public offerings (IPOs) and secondaries, and the market has become so oversaturated that some of the ...
Read Full Story »
Biotechnology word cloud

Short Sellers Look Scared of Big Biotech

The short interest data are out for the January 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Wall Street

Insiders Aggressively Buy Shares as Market Rockets Higher

Logically, it seems that as they stock market zooms higher, insiders who want to buy stock would wait until a pullback to add new capital. If this week's action is ...
Read Full Story »
Stock Split Image

Gilead Dividend and Buyback Different From Amgen’s Strategy

Most investors invest in biotech companies for their drug pipelines and endless growth potential. The problem is that eventually biotech companies can get so large that they are effectively just ...
Read Full Story »
Biotechnology word cloud

Short Sellers Starting to Gang Up on Biotech

The short interest data are out for the January 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Biotechnology word cloud

Short Interest in Biotechs Signals Optimism

The short interest data are out for the December 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
fda_logo

Is a Biosimilar (Generic) Top Cancer Drug for You?

There has been a movement to get generic pharmaceutical drugs to market with for years. The notion of "biosimilars" has grown as well. Effectively this is making biotech drugs into ...
Read Full Story »
biotech

Are Investors Signaling Optimism in Biotechs Through Short Interest?

The short interest data are out for the November 28 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
DNA

Mixed Readings For Biotech Short Interest

The short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
145922793

Amgen Surprise, Discontinues Stomach Cancer Drug Study

Amgen Inc. (NASDAQ: AMGN) announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer. This includes phase 3 RILOMET-1 and RILOMET-2 studies. The decision to discontinue ...
Read Full Story »
Biotechnology word cloud

Biotech Short Interest Becomes Stock Specific (Updated)

The short interest data are out for the October 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
health care

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Many investors want to try to find the stocks that are going to offer the traditional “beat and raise estimates” before they release quarterly earnings reports. Actually, it has always ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Alibaba, Amgen, Cliffs, Michael Kors, Sanofi, Yahoo! and More

Stocks are looking for direction on Wednesday with mixed indexes, but that is after another massive rally on Tuesday that took the DJIA back over 17,000 again. Earnings season is ...
Read Full Story »
Pills

Amgen Posts 52-Week High, Beats It Again After Earnings

Drug maker Amgen Inc. (NASDAQ: AMGN) reported third-quarter 2014 results after markets closed Monday afternoon. The biotech company reported quarterly adjusted diluted earnings per share (EPS) of $2.30 and revenues ...
Read Full Story »